Literature DB >> 15796757

Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.

D McFarlane1, N Dybdal, M T Donaldson, L Miller, A E Cribb.   

Abstract

Equine pituitary pars intermedia dysfunction (PPID) is a spontaneously occurring progressive disease affecting aged horses and ponies. The pathogenesis of PPID is poorly understood, but the available evidence supports a loss of dopaminergic inhibition of the melanotropes of the pars intermedia. Horses with PPID have increased plasma concentrations of pars intermedia pro-opiomelanocortin-derived peptides that decrease in response to dopamine or dopamine agonist administration. Dopamine and dopamine metabolite concentrations are decreased in the pars intermedia of affected horses compared to age-matched control horses. Horses with disease that are treated with the dopamine agonist pergolide show improvement in clinical signs and normalisation of diagnostic test results. In the present study, immunohistochemical evaluation of pituitary and hypothalamic tissue demonstrated reduced tyrosine hydroxylase immunoreactivity in affected horses compared to age-matched and young controls, supporting the role of dopaminergic neurodegeneration in PPID. In addition, immunohistochemical evaluation revealed an increase in the oxidative stress marker, 3-nitrotyrosine and in nerve terminal protein, alpha-synuclein that colocalised in the pars intermedia of horses with disease. These findings suggest a role for nitration of overexpressed alpha-synuclein in the pathogenesis of neurodegeneration in PPID.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15796757     DOI: 10.1111/j.1365-2826.2005.01277.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  17 in total

1.  Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.

Authors:  James L Carmalt; Cheryl L Waldner; Andrew L Allen
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

Review 2.  Diabetes, insulin resistance, and metabolic syndrome in horses.

Authors:  Philip J Johnson; Charles E Wiedmeyer; Alison LaCarrubba; V K Ganjam; Nat T Messer
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

3.  Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Authors:  Marta Martinez-Vicente; Zsolt Talloczy; Susmita Kaushik; Ashish C Massey; Joseph Mazzulli; Eugene V Mosharov; Roberto Hodara; Ross Fredenburg; Du-Chu Wu; Antonia Follenzi; William Dauer; Serge Przedborski; Harry Ischiropoulos; Peter T Lansbury; David Sulzer; Ana Maria Cuervo
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 4.  Medical implications of obesity in horses--lessons for human obesity.

Authors:  Philip J Johnson; Charles E Wiedmeyer; Nat T Messer; Venkataseshu K Ganjam
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 5.  Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies.

Authors:  Belém Sampaio-Marques; Paula Ludovico
Journal:  Biomolecules       Date:  2015-05-04

6.  Pituitary pars intermedia dysfunction (equine Cushing's disease) in a Thoroughbred stallion: a single report.

Authors:  Takashi Hatazoe; Hiroaki Kawaguchi; Seiji Hobo; Kazuhiro Misumi
Journal:  J Equine Sci       Date:  2016-02-03

7.  Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.

Authors:  James L Carmalt; Sima Mortazavi; Rebecca C McOnie; Andrew L Allen; Suraj Unniappan
Journal:  PLoS One       Date:  2018-01-08       Impact factor: 3.240

8.  Seasonal changes in circadian peripheral plasma concentrations of melatonin, serotonin, dopamine and cortisol in aged horses with Cushing's disease under natural photoperiod.

Authors:  S J A Haritou; R Zylstra; C Ralli; S Turner; D J Tortonese
Journal:  J Neuroendocrinol       Date:  2008-06-06       Impact factor: 3.627

9.  Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.

Authors:  Jessica S Fortin; Ashley A Hetak; Kelsey E Duggan; Caroline M Burglass; Hailey B Penticoff; Harold C Schott
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

10.  Salidroside Promotes the Pathological α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells.

Authors:  Tao Li; Yang Feng; Ruixin Yang; Leitao Wu; Ruru Li; Lu Huang; Qian Yang; Jianzong Chen
Journal:  Front Pharmacol       Date:  2018-04-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.